All news

Adaptive Biotechnologies COO sells 11,881 shares

Alpha Vantage · MarketBeat · · AI-summarised by FinFlash

Adaptive Biotechnologies COO Julie Rubinstein sold 11,881 shares at an average price of $24.98, roughly $296,787, cutting her direct ownership by 3.05%. The sale was made under a pre-arranged Rule 10b5-1 trading plan. Analysts hold a Moderate Buy consensus with an average price target of $30.06, even after the company posted a wider-than-expected quarterly loss per share.

Read original source

ADPT company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.